KLRK1 and myelodysplastic syndrome: NKX101, engineered to target NKG2D ligands on cancer cells, showed striking early single-agent activity and no dose-limiting toxicities in R/R AML or myelodysplastic syndromes (MDS) patient populations [NCT04623944].